Veracyte Inc. Aktie
Deine Einschätzung
Veracyte Inc. Aktie
Was spricht für und gegen Veracyte Inc. in den nächsten Jahren?
Pro
Kontra
Rendite von Veracyte Inc. im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Veracyte Inc. | -1,58 % | -5,09 % | -8,13 % | 126,98 % | 33,67 % | 94,03 % | 44,94 % |
| Evolus Inc | -0,50 % | 4,55 % | -13,72 % | -32,48 % | -2,13 % | -41,38 % | -42,02 % |
| Heron Therapeutics Inc. | 1,53 % | 1,96 % | 14,43 % | -73,49 % | -61,71 % | -69,53 % | -96,01 % |
| Rhythm Pharmaceuticals | -1,08 % | 3,31 % | -2,60 % | 28,08 % | 0,00 % | 491,77 % | 495,54 % |
Kommentare
News
A Veracyte Insider Sold 24,000 Company Shares for $1.1 Million. Here's a Deeper Look at the Transaction.
Jonathan Wygant, Vice President and Chief Accounting Officer of Veracyte (NASDAQ:VCYT), reported the exercise of 24,000 options and immediate open-market sale of the same number of shares for a
What to Know About This $197,000 Veracyte Insider Sale After a 120% Stock Rally
Karin Eastham, a director of Veracyte (NASDAQ:VCYT), reported the sale of 3,729 shares of common stock in multiple open-market transactions on June 18, 2026, as detailed in the SEC Form 4 filing.
Why Veracyte Stock Is Skyrocketing Higher This Week
Shares of leading diagnostics platform and cancer-detecting genomic test provider Veracyte (NASDAQ: VCYT) are up 23% over the last week as of market close Thursday, after the company reported




